Synonym
Terazocin HCl; Vasocard; Hyprin; A-45975; A 45975; A45975
IUPAC/Chemical Name
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-, monohydrochloride
InChi Key
IWSWDOUXSCRCKW-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H
SMILES Code
O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
423.90
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: An GH, Kim MJ, Lee HJ, Park SS, Cho YW, Park K, Choa YH. Fabrication of terazocin-loaded poly(D,L-lactide) microspheres by an ultrasonic spray drying method and their release behaviors. J Nanosci Nanotechnol. 2008 Oct;8(10):5139-42. PubMed PMID: 19198407.
2: Liu G. [Effects of terazocin on hypertensive patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 1990 Oct;18(5):271-2. Chinese. PubMed PMID: 1982259.
3: Kotridis P, Kokkas B, Kyriakou P, Karamouzis M, Salpigidis G, Karantona C, Karadoumanis J, Ginis T, Goulis O, Papadopoulos PC, Vakalopoulos C, Sakantamis G, Dimitriadou A, Mirtsou-Fidani V, Papadopoulos CL. Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin. Eur J Drug Metab Pharmacokinet. 2003 Apr-Jun;28(2):143-6. PubMed PMID: 12877573.
4: Pawar A, Fahim M. Baroreceptor mediated blood pressure regulation is not affected during dose dependent inhibition of prostatic contractions by terazosin. Indian J Physiol Pharmacol. 2004 Oct;48(4):419-27. PubMed PMID: 15907050.
